跳至主要内容
临床试验/NL-OMON56494
NL-OMON56494尚未招募不适用

Early detection of the effectiveness of treatment with biologicals in patients with severe asthma using fluctuation analysis of biomarkers - FABLE (Fluctuation analysis in asthma and biologics use)

Academisch Medisch Centrum0 个研究点目标入组 48 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
48

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 64(—)

入选标准

  • Severe asthma based on the definition by the 2022 GINA guidelines.
  • Will start treatment with a biological
  • 18-60 years old
  • Subject should be willing and able to perform the lung function tests and
  • other study-related procedures and comply with study protocol requirements.
  • Apart from their asthma, subjects should be generally healthy with no history
  • of a clinically relevant medical condition that in the opinion of the
  • investigator might interfere with successful study conduct and no clinically
  • relevant abnormalities on medical history.
  • Subjects should provide a signed and dated informed consent

排除标准

  • Has been tested positively for COVID-19 in the past month or has not fully
  • recovered from an earlier COVID-19 infection (e.g. post-covid syndrome) • Has
  • been treated with oral corticosteroids as high-dose therapy in the 6 weeks
  • before visit 1. • Has been treated with another biologic within 3 months before
  • start treatment with new biological (e.g. 2 months before the start of the
  • study participation) • Not able to perform spirometry/IOS/FeNO tests correctly
  • Not able to handle Respicorder well • Subject is a current smoker/vaper, uses
  • recreational drugs, or has >10 packyears • Subject is anticipated not to comply
  • with study protocol or other aspects of the study (at the discretion of the
  • investigator) • Participation to the study is not medically responsible
  • according to the study physician and/or principle investigator • Inability to
  • read and/or understand the Dutch language

研究者

相似试验